Chilmark Research October 15, 2020
Jody Ranck

While COVID-19 has been dominating the healthcare headlines so far in 2020 there have been a number of recent policy and regulatory decisions bearing on the AI/ML market in healthcare. We have been reading quite a bit about the broader slowdown in the market for AI/ML developers since the pandemic began that may be a temporary disruption to some parts of the market. On the other hand, CMS and the FDA have made some moves that may be part of building a stronger foundation for the market in AI applications, at least in clinical decision support and radiology/medical imaging segments of the market. We have also seen some major bets placed on AI-based companies that are riding on the wave...

Today's Sponsors

SalesSparx
Canton & Company
Oscar

Today's Sponsors

HLTH
ZeOmega

Today's Sponsor

Crossover Health

 
Topics: AI (Artificial Intelligence), CMS, FDA, Govt Agencies, Healthcare System, Investments, Public Health / COVID, Regulations, Technology, Trends
AI Weekly: U.S. agencies are increasing their AI investments
71% of Healthcare Execs to Invest in AI Over the Next Three Years
What Databricks’s $1.6B funding round means for the enterprise AI market
How transparent design helped a startup win CMS’ AI challenge — and $34M in funding
Nvidia is tracking more than 8,500 AI startups with $60B in funding